News

People who received five or more courses of penicillin antibiotic treatment in the five years before a Parkinson’s diagnosis had an approximately 15% lower risk of developing the disease than those who took no antibiotics, according to a Rutgers Health study. Conversely, treatment with two or more courses of…

The planned Phase 2 SUNRISE-PD clinical trial of oral bezisterim as a first-line, stand-alone treatment for newly diagnosed Parkinson’s disease patients is scheduled to begin in early 2025. BioVie, the therapy’s developer, has secured over $15 million to cover complete costs of the trial, and top-line findings are…

Lianna Genovese, the 25-year-old founder of Imaginable Solutions and the inventor of Guided Hands, a device that helps individuals with limited hand mobility, was recognized with the 2024 Muhammad Ali Humanitarian Award. Various conditions can limit a person’s ability to write, draw, dress themselves, or use technology, including…

Zimmer Biomet announced that it has acquired select exclusive rights to distribute NeuroOne’s OneRF Ablation System, a brain electrode-guided tool for use in neurological brain surgeries, including those for Parkinson’s disease. “As the world’s first FDA [U.S. Food and Drug Administration] cleared system for both diagnostic…

Side-to-side eye movements can help reduce body sway and improve postural stability in people with Parkinson’s disease, even though Parkinson’s patients generally have difficulty coordinating their eye movements, a new study reports. The study, “People with Parkinson’s Disease Are Able to Couple Eye Movements and Postural…

A type of RNA structure called G-quadruplex, or G4 — a four-stranded RNA structure that forms when calcium enters cells in response to stress — may offer a scaffold for the alpha-synuclein protein to clump together and become toxic to nerve cells in Parkinson’s disease, research suggests. In a…

Sunbird Bio’s blood test to indirectly detect toxic clumps of alpha-synuclein protein in the brain, a hallmark of Parkinson’s disease, may help yield an accurate Parkinson’s diagnosis, according to data from a clinical study. The company presented the results in a poster, “Using neural derived EV-bound biomarkers in…

The U.S. Food and Drug Administration (FDA) has set Feb. 1, 2025, as a goal date for deciding whether to approve SPN-830, an apomorphine infusion pump, for the continuous treatment of off episodes in Parkinson’s disease. That’s according to a financial update from the device’s developer,…

The Cleveland Clinic’s Center for Neurological Restoration, which specializes in medical and surgical approaches for treating Parkinson’s disease and other neurological and movement disorders, has once again been recognized as a Center of Excellence by the Parkinson’s Foundation. It was previously awarded the designation in 2018. That designation…

Delphi-MD, a system that measures brain activity, may be used for the early diagnosis of Parkinson’s disease and for differentiating between its subtypes, particularly those marked by rapid disease progression, a study shows. The technology, developed by Quantalx Neuroscience, provides direct, real-time imaging of the brain’s electrical…